John L. Xu

Company: GeneScience Pharmaceutical Co

Job title: Executive Vice President, Pharmaceutical R&D

Seminars:

11:30am Bispecific Antibody-Drug Conjugates for Targeted Cancer Therapy 11:30 am

Acquired resistance presents a major challenge to the development of ADC drugs, and dual targeting may be one solution to overcome it GenSci’s novel ADC technology platform and robust bispecific ADC pipeline; GenSci139, a highly differentiated and potential best-in-class EGFR×HER2 BsADC, for targeted therapy in multiple solid tumors; GenSci143, a highly differentiated B7-H3 x PSMA…Read more

day: Bispecific ADC Seminar Day